Traders Buy Stryker (SYK) on Weakness

Investors purchased shares of Stryker Corporation (NYSE:SYK) on weakness during trading on Monday. $64.94 million flowed into the stock on the tick-up and $30.83 million flowed out of the stock on the tick-down, for a money net flow of $34.11 million into the stock. Of all equities tracked, Stryker had the 24th highest net in-flow for the day. Stryker traded down ($0.37) for the day and closed at $158.23

Several analysts recently weighed in on SYK shares. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $161.00 to $173.00 in a report on Thursday, November 16th. JPMorgan Chase & Co. upgraded shares of Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. BMO Capital Markets upgraded shares of Stryker to a “market perform” rating and set a $163.00 price target on the stock in a report on Tuesday, December 12th. Finally, Stifel Nicolaus lifted their price target on shares of Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. Stryker presently has a consensus rating of “Hold” and an average target price of $156.60.

The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market cap of $59,220.00, a PE ratio of 33.74, a P/E/G ratio of 2.27 and a beta of 0.78.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.39 earnings per share. equities analysts predict that Stryker Corporation will post 6.49 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.88 annualized dividend and a yield of 1.19%. This is a positive change from Stryker’s previous quarterly dividend of $0.43. Stryker’s dividend payout ratio (DPR) is currently 40.09%.

In other news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 7.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of SYK. Acrospire Investment Management LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $111,000. Motco raised its position in Stryker by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after buying an additional 278 shares during the last quarter. Sawyer & Company Inc purchased a new position in Stryker in the 4th quarter worth about $125,000. Sit Investment Associates Inc. raised its position in Stryker by 114.3% in the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock worth $128,000 after buying an additional 440 shares during the last quarter. Finally, San Francisco Sentry Investment Group CA raised its position in Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after buying an additional 325 shares during the last quarter. 74.88% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This news story was reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://weekherald.com/2018/01/15/traders-buy-stryker-syk-on-weakness.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply